Citations (35)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Shijie Xu, Fangbo Cui, Dafu Huang, Dinghu Zhang, Anqing Zhu, Xia Sun, Yiming Cao, Sheng Ding, Yao Wang, Eryun Gao & Fenglin Zhang. (2019) PD-L1 monoclonal antibody-conjugated nanoparticles enhance drug delivery level and chemotherapy efficacy in gastric cancer cells. International Journal of Nanomedicine 14, pages 17-32.
Read now
Read now
Articles from other publishers (34)
Moataz Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A. Crumrine, Justin P. C. Rehwaldt, Akash Bindal, Gordon B. Mills, Joe W. Gray & Wassana Yantasee. (2022) Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment. Nature Communications 13:1.
Crossref
Crossref
Norifumi Iseda, Shinji Itoh, Tomoharu Yoshizumi, Takahiro Tomiyama, Akinari Morinaga, Kyohei Yugawa, Masahiro Shimokawa, Tomonari Shimagaki, Huanlin Wang, Takeshi Kurihara, Yoshiyuki Kitamura, Yoshihiro Nagao, Takeo Toshima, Noboru Harada, Kenichi Kohashi, Shingo Baba, Kousei Ishigami, Yoshinao Oda & Masaki Mori. (2021) Impact of Nuclear Factor Erythroid 2–Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatology Communications 6:4, pages 665-678.
Crossref
Crossref
Cinzia Garofalo, Carmela De Marco & Costanza Maria Cristiani. (2021) NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. Frontiers in Oncology 11.
Crossref
Crossref
Elmira Roshani Asl, Yousef Rasmi & Behzad Baradaran. (2021) MicroRNA‐124‐3p suppresses PD‐L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling. Journal of Cellular Physiology 236:10, pages 7071-7087.
Crossref
Crossref
Hazem Ghebeh, Adher Al-Sayed, Riham Eiada, Leilani Cabangon, Dahish Ajarim, Kausar Suleman, Asma Tulbah & Taher Al-Tweigeri. (2021) Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer. Scientific Reports 11:1.
Crossref
Crossref
Qiang Wen, Zhe Yang, Honghai Dai, Alei Feng & Qiang Li. (2021) Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Frontiers in Oncology 11.
Crossref
Crossref
Marzia Del Re, Caterina Vivaldi, Eleonora Rofi, Francesca Salani, Stefania Crucitta, Silvia Catanese, Lorenzo Fontanelli, Valentina Massa, Federico Cucchiara, Lorenzo Fornaro, Annalisa Capuano, Stefano Fogli, Enrico Vasile & Romano Danesi. (2021) Gemcitabine Plus Nab-Paclitaxel Induces PD-L1 mRNA Expression in Plasma-Derived Microvesicles in Pancreatic Cancer. Cancers 13:15, pages 3738.
Crossref
Crossref
Daniel Lenouvel, Miguel Ángel González‐Moles, Isabel Ruiz‐Ávila, Clara Chamorro‐Santos, Lucía González‐Ruiz, Isabel González‐Ruiz & Pablo Ramos‐García. (2020) Clinicopathological and prognostic significance of PD‐L1 in oral cancer: A preliminary retrospective immunohistochemistry study. Oral Diseases 27:2, pages 173-182.
Crossref
Crossref
Xia Wu, Yangyang Meng, Lei Liu, Guowei Gong, Haotian Zhang, Yunlei Hou, Chunyang Liu, Di Wu & Mingze Qin. (2021) Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. Bioorganic & Medicinal Chemistry 33, pages 116038.
Crossref
Crossref
Kohei Yamashita, Masaaki Iwatsuki, Noriko Yasuda-Yoshihara, Takeshi Morinaga, Yosuke Nakao, Kazuto Harada, Kojiro Eto, Junji Kurashige, Yukiharu Hiyoshi, Takatsugu Ishimoto, Yohei Nagai, Shiro Iwagami, Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, Jaffer A. Ajani & Hideo Baba. (2020) Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. British Journal of Cancer 124:3, pages 595-603.
Crossref
Crossref
Yu Wang, Qingguo Sun, Ning Mu, Xiaoyang Sun, Yingying Wang, Songqing Fan, Ling Su & Xiangguo Liu. (2020) The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells. Cell Communication and Signaling 18:1.
Crossref
Crossref
Min Zhang, Yibo Fan, Xiaofang Che, Kezuo Hou, Chaoxu Zhang, Ce Li, Ti Wen, Shuo Wang, Yu Cheng, Yunpeng Liu & Xiujuan Qu. (2020) 5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. Frontiers in Oncology 10.
Crossref
Crossref
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila & José Antonio Gil‐Montoya. (2019) An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases 26:3, pages 511-526.
Crossref
Crossref
Q Sheng, Y Zhang, Z Wang, J Ding, Y Song & W Zhao. (2020) Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells. Clinical and Experimental Immunology 200:1, pages 45-52.
Crossref
Crossref
Tiankuan Li, Zhongqian Hu, Chao Wang, Jian Yang, Chuhui Zeng, Rui Fan & Jinhe Guo. (2020) PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect for the treatment of lung cancer under ultrasound irradiation. Biomaterials Science 8:5, pages 1418-1430.
Crossref
Crossref
Gulzar Ahmad, Gerardo G. Mackenzie, James Egan & Mansoor M. Amiji. (2019) DHA-SBT-1214 Taxoid Nanoemulsion and Anti–PD-L1 Antibody Combination Therapy Enhances Antitumor Efficacy in a Syngeneic Pancreatic Adenocarcinoma Model. Molecular Cancer Therapeutics 18:11, pages 1961-1972.
Crossref
Crossref
Zhen Tao, Hailong Ruan, Lin Sun, Dong Kuang, Yongchun Song, Qi Wang, Tao Wang, Yi Hao & Ke Chen. (2019) Targeting the YB-1/PD-L1 Axis to Enhance Chemotherapy and Antitumor Immunity. Cancer Immunology Research 7:7, pages 1135-1147.
Crossref
Crossref
Xiangfeng Shen, Lihong Zhang, Jicheng Li, Yulin Li, Yishu Wang & Zhi-Xiang Xu. (2019) Recent Findings in the Regulation of Programmed Death Ligand 1 Expression. Frontiers in Immunology 10.
Crossref
Crossref
Zhishan Xu, Yujiao Zhang, Shumiao Zhang, Xianglei Jia, Genshen Zhong, Yuliang Yang, Qing Du, Juanjuan Li & Zhe Liu. (2019) Novel half-sandwich iridium OˆC (carbene)-Complexes: In vitro and in vivo tumor growth suppression and pro-apoptosis via ROS-mediated cross-talk between mitochondria and lysosomes. Cancer Letters 447, pages 75-85.
Crossref
Crossref
Fatemeh K. Dermani, Pouria Samadi, Golebagh Rahmani, Alisa K. Kohlan & Rezvan Najafi. (2018) PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology 234:2, pages 1313-1325.
Crossref
Crossref
Tingkai Chen, Qi Li, Zongliang Liu, Yao Chen, Feng Feng & Haopeng Sun. (2019) Peptide-based and small synthetic molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy?. European Journal of Medicinal Chemistry 161, pages 378-398.
Crossref
Crossref
Edwin R. Parra, Pamela Villalobos, Carmen Behrens, Mei Jiang, Apar Pataer, Stephen G. Swisher, William N. William, Jiexin Zhang, Jack Lee, Tina Cascone, John V. Heymach, Marie-Andrée Forget, Cara Haymaker, Chantale Bernatchez, Neda Kalhor, Annikka Weissferdt, Cesar Moran, Jianjun Zhang, Ara Vaporciyan, Don L. Gibbons, Boris Sepesi & Ignacio I. Wistuba. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. Journal for ImmunoTherapy of Cancer 6:1.
Crossref
Crossref
Hoi Yan Ng, Jian Li, Lihua Tao, Alfred King-Yin Lam, Kwok Wah Chan, Josephine Mun Yee Ko, Valen Zhuoyou Yu, Michael Wong, Benjamin Li & Maria Li Lung. (2018) Chemotherapeutic Treatments Increase PD-L1 Expression in Esophageal Squamous Cell Carcinoma through EGFR/ERK Activation. Translational Oncology 11:6, pages 1323-1333.
Crossref
Crossref
Ioannis Zerdes, Alexios Matikas, Jonas Bergh, George Z. Rassidakis & Theodoros Foukakis. (2018) Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. Oncogene 37:34, pages 4639-4661.
Crossref
Crossref
Cui‑Juan Qian, Yong‑Xiao Qi, Sheng Zhong, Ju‑Ping Zeng, Xiao‑Ying Chen & Jun Yao. (2018) Mitogen‑activated protein kinase inhibition enhances the antitumor effects of sporamin in human pancreatic cancer cells. Oncology Letters.
Crossref
Crossref
Mi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hye Kyung Lee, Ho Suk Kang & Kyueng-Whan Min. (2017) Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection. Oncotarget 8:47, pages 82399-82414.
Crossref
Crossref
Toshifumi Doi, Takeshi Ishikawa, Tetsuya Okayama, Kaname Oka, Katsura Mizushima, Tomoyo Yasuda, Naoyuki Sakamoto, Kazuhiro Katada, Kazuhiro Kamada, Kazuhiko Uchiyama, Osamu Handa, Tomohisa Takagi, Yuji Naito & Yoshito Itoh. (2017) The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncology Reports 37:3, pages 1545-1554.
Crossref
Crossref
Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar & Michael T. Lotze. (2016) 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. Journal for ImmunoTherapy of Cancer 4:1.
Crossref
Crossref
Jessica Chacon, Keith Schutsky & Daniel Powell. (2016) The Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor Efficacy. Vaccines 4:4, pages 43.
Crossref
Crossref
Enli Liu, Jie Li, Shasha Shi, Xiaojian Wang, Taigang Liang, Bowei Wu & Qingshan Li. (2016) Sustained ERK activation-mediated proliferation inhibition of farrerol on human gastric carcinoma cell line by G0/G1-phase cell-cycle arrest. European Journal of Cancer Prevention 25:6, pages 490-499.
Crossref
Crossref
J. Chen, C.C. Jiang, L. Jin & X.D. Zhang. (2016) Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Annals of Oncology 27:3, pages 409-416.
Crossref
Crossref
Andrew S. McDaniel, Ajjai Alva, Tianyu Zhan, Hong Xiao, Xuhong Cao, Amy Gursky, Javed Siddiqui, Arul M. Chinnaiyan, Hui Jiang, Cheryl T. Lee & Rohit Mehra. (2016) Expression of PDL1 (B7-H1) Before and After Neoadjuvant Chemotherapy in Urothelial Carcinoma. European Urology Focus 1:3, pages 265-268.
Crossref
Crossref
Kannan Badri Narayanan, Manaf Ali, Barry J. Barclay, Qiang (Shawn) Cheng, Leandro D’Abronzo, Rita Dornetshuber-Fleiss, Paramita M. Ghosh, Michael J. Gonzalez Guzman, Tae-Jin Lee, Po Sing Leung, Lin Li, Suidjit Luanpitpong, Edward Ratovitski, Yon Rojanasakul, Maria Fiammetta Romano, Simona Romano, Ranjeet K. Sinha, Clement Yedjou, Fahd Al-Mulla, Rabeah Al-Temaimi, Amedeo Amedei, Dustin G. Brown, Elizabeth P. Ryan, Anna Maria Colacci, Roslida A. Hamid, Chiara Mondello, Jayadev Raju, Hosni K. Salem, Jordan Woodrick, A.Ivana Scovassi, Neetu Singh, Monica Vaccari, Rabindra Roy, Stefano Forte, Lorenzo Memeo, Seo Yun Kim, William H. Bisson, Leroy Lowe & Hyun Ho Park. (2015) Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis 36:Suppl 1, pages S89-S110.
Crossref
Crossref
Qiong Liu, Wenrong GongZhengjiang Cheng, Hua Jiang, Fengsheng Cao & Xianxian Li. (2013) Counteracting immunosuppressive cofactor B7-H1 may enhance the effects of chemotherapy in cancer patients. Immunotherapy 5:6, pages 557-559.
Crossref
Crossref